EXSCEL—once-weekly exenatide reduces medical resource utilization in patients with type 2 diabetes mellitus

EXSCEL—once-weekly exenatide reduces medical resource utilization in patients with type 2 diabetes mellitus

Bibliographic Details
Main Authors:	Reed, S, Li, Y, Dakin, H, Becker, F, Leal, J, Gustavson, S, Kartman, B, Wittbrodt, E, Mentz, R, Pagidipati, N, Bethel, M, Gray, A, Holman, R, Hernandez, A
Format:	Conference item
Published:	American Diabetes Association 2018

Similar Items

Impact of exenatide on medical costs and health utilities in type 2 diabetes: experience from EXSCEL
by: Reed, S, et al.
Published: (2018)

Lifetime cost-effectiveness simulation of exenatide once-weekly in type 2 diabetes: evidence from the EXSCEL trial
by: Becker, F, et al.
Published: (2018)

Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: a cost-utility analysis based on the EXSCEL trial
by: Becker, F, et al.
Published: (2021)

Within-trial evaluation of medical resources, costs, and quality of life among patients with type 2 diabetes participating in the exenatide study of cardiovascular event lowering (EXSCEL)
by: Reed, S, et al.
Published: (2019)

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
by: Mentz, R, et al.
Published: (2017)

Rationale and design of the EXenatide study of cardiovascular event lowering (EXSCEL) trial
by: Holman, R, et al.
Published: (2015)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
by: Jason Seewoodhary, et al.
Published: (2010-05-01)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
by: Seewoodhary J, et al.
Published: (2010-05-01)

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
by: Mann KV, et al.
Published: (2014-06-01)

Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial
by: Mette Kruse Klausen, et al.
Published: (2022-10-01)

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
by: MacConell L, et al.
Published: (2015-05-01)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
by: Saunders WB, et al.
Published: (2016-07-01)

New indications for exenatide therapy of type 2 diabetes mellitus
by: Olga Konstantinovna Vikulova, et al.
Published: (2010-09-01)

An antiinflammatory actions of exenatide
Published: (2012-12-01)

The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults [version 2; peer review: 2 approved]
by: Sharon Lechtig-Wassermann, et al.
Published: (2023-12-01)

Addition of exenatide to insulin therapy in individuals with type 2 diabetes in UK routine clinical practice
by: Price, H, et al.
Published: (2012)

Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study
by: Ji Young Seo, et al.
Published: (2023-02-01)

Commentary on "Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study"
by: Han Hyuk Lim
Published: (2023-12-01)

The Effect of Once-Weekly 70 Mg Alendronate Versus Once-Daily 10 Mg Alendronate in the Treatment of Postmenopausal Osteoporosis
by: İlker Çorapçı, et al.
Published: (2004-03-01)

GLYCEMIC AND NON-GLYCEMIC EFFECTS OF EXENATIDE IN PATIENTS WITH DIABETES MELLITUS OF TYPE 2 (DM2) WITH MYOCARDIAL INFARCTION
by: A. Yu. BABENKO, et al.
Published: (2016-12-01)

Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus
by: Jie Zhang, et al.
Published: (2022-01-01)

Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
by: Fieke W. Hoff, et al.
Published: (2024-03-01)

The Effects of pH and Excipients on Exenatide Stability in Solution
by: Alexander Benet, et al.
Published: (2021-08-01)

Exenatide improves glucocorticoid-induced glucose intolerance in mice
by: Ruiying Zhao, et al.
Published: (2011-01-01)

Association between exenatide use and incidence of Alzheimer's disease
by: Bo Zhou, et al.
Published: (2021-01-01)

Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease.
by: Sungmin Kim, et al.
Published: (2022-01-01)

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01)

Exenatide for obesity in children and adolescents: Systematic review and meta-analysis
by: Bin Chen, et al.
Published: (2024-04-01)

EVALUATION OF CARDIOPROTECTIVE EFFECTS OF THE INCRITIN MIMETICS EXENATIDE AND VILDAGLIPTIN IN THE EXPERIMENT
by: Alla Tarasova, et al.
Published: (2017-06-01)

Exenatide Microspheres for Monthly Controlled-Release Aided by Magnesium Hydroxide
by: Yuxuan Ge, et al.
Published: (2021-05-01)

Examination of quality of life in patients using exenatide with different dimensions
by: Siddika Ersoy, et al.
Published: (2022-05-01)

ACUTE PANCREATITIS ASSOCIATED WITH EXENATIDE AND LIRAGLUTIDE: A META-ANALYSIS
by: Carlos Alves, et al.
Published: (2012-09-01)

Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
by: Price, D, et al.
Published: (2011)

COOK ONCE eat ALL WEEK : 26 weeks of gluten-free, affordable meal prep to preserve your time & sanity /
by: Garcia, Cassy Joy, author
Published: (2019)

Exenatide and Metformin Improve Serum Indices and Intestinal Flora in patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease
by: Xiaojie Jiang, et al.
Published: (2023-12-01)

Economic evaluation of factorial trials: cost-utility analysis of the AFORRD 2x2x2 factorial trial of atorvastatin, omega-3 fish oil and action-planning
by: Dakin, HA, et al.
Published: (2020)

Randomized controlled trial comparing impact on platelet reactivity of twice‐daily with once‐daily aspirin in people with type 2 diabetes
by: Bethel, M, et al.
Published: (2016)

Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
by: A.B.M. Kamrul-Hasan, et al.
Published: (2024-02-01)

EFFECT OF PHARMACOLOGICAL PRECONDITIONING WITH INCRETINOMIMETICS EXENATIDE AND VILDAGLIPTIN ON THE SURVIVAL OF ISCHEMIC TISSUES
by: Alla Tarasova, et al.
Published: (2017-12-01)

New-Onset Atrial Fibrillation After Exenatide Injection: Coincidence or Consequence?
by: Yakup Yunus Yamantürk, et al.
Published: (2023-10-01)